Future Directions in GVHD
Pashna Munshi, MD, wraps up by talking about future directions and emerging treatment regimens in the field of GVHD.
Case: A 58-Year-Old Man With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease
Initial Presentation
- A 58-year-old man previously underwent myeloablative conditioning and an allogeneic PBSC transplant for acute lymphocytic leukemia
- Received tacrolimus and methotrexate for GVHD prophylaxis
- At 10 months post-transplant, patient developed moderate muscle and joint pain with decreased range of motion, mild erythematous rash on cheeks
First-line Treatment
- Patient received topical steroid cream for rash, and was started on oral prednisone at 1 mg/kg/day
- After 4 weeks of treatment, the patient’s rash resolved but muscle/joint pain continued
Second-line Treatment
- Patient is now receiving ruxolitinib 10 mg orally twice daily, alongside 1 mg/kg/day steroids
Recent Videos
Related Content
Iomab-B Leads to More Durable Responses vs alloHCT in AML Treatment
September 24th 2024Article
Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs allogeneic cell transplant in older patients with relapsed/refractory acute myeloid leukemia.
Read More
